According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
According to a study led by University of Michigan researchers, fewer than one-third of hospitals had immediate availability of all-trans retinoic acid (ATRA), which is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting, and potential death.
In findings led by researchers at Yale Cancer Center and collaborating institutions, the monoclonal antibody drug sotigalimab, combined with Bristol Myers Squibb’s immunotherapy drug Opdivo (nivolumab), resulted in tumor shrinkage in patients with advanced melanoma whose tumors had progressed on prior immunotherapy.
A study led by Yale Cancer Center found that more men received a prostate-specific antigen (PSA) test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening.
An analysis from the American Cancer Society, appearing in JAMA Oncology, quantified the progress made against cancer since the passage of the National Cancer Act fifty years ago.
Combination treatment with immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated overall survival benefit for patients with melanoma that has spread to the brain, according to phase II study results published in The Lancet Oncology by researchers at MD Anderson Cancer Center.
The neoadjuvant Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone in patients with with resectable stage IB to IIIA non-small cell lung cancer, according to a prespecified interim analysis of the phase III CheckMate -816 trial.
A clinical trial conducted by the Children’s Oncology Group and funded by NCI found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia.
Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy found that combining Medimmune/AstraZeneca’s immunotherapy agent Imfinzi (durvalumab) with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma.
A team of scientists led by Rong Lu from USC and Akil A. Merchant from Cedars-Sinai introduced a genetic technology correlating gene expression signatures with cancer progression and chemotherapy resistance in leukemia.
